Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Capital Expenditures (2017 - 2021)

Rein Therapeutics (RNTX) has disclosed Capital Expenditures for 4 consecutive years, with $5000.0 as the latest value for Q3 2021.

  • Quarterly Capital Expenditures changed N/A to $5000.0 in Q3 2021 from the year-ago period, while the trailing twelve-month figure was $157000.0 through Dec 2021, up 685.0% year-over-year, with the annual reading at $157000.0 for FY2021, 3040.0% up from the prior year.
  • Capital Expenditures for Q3 2021 was $5000.0 at Rein Therapeutics, down from $67000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $2.3 million in Q3 2018, with the low at $4000.0 in Q2 2019.
  • Average Capital Expenditures over 4 years is $221266.7, with a median of $38000.0 recorded in 2017.
  • The sharpest move saw Capital Expenditures skyrocketed 8337.04% in 2018, then plummeted 99.78% in 2019.
  • Over 4 years, Capital Expenditures stood at $68000.0 in 2017, then soared by 455.88% to $378000.0 in 2018, then tumbled by 96.03% to $15000.0 in 2019, then tumbled by 66.67% to $5000.0 in 2021.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $5000.0, $67000.0, and $85000.0 for Q3 2021, Q2 2021, and Q1 2021 respectively.